Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Stain-Free Histology

Nanophotonic slides add color to tissue samples

Rather than relying on chemical dyes, researchers have developed a method to enhance the cellular features in pathology slides based on “structural color” – the same effect that gives peacock…

News • Neuroprotective antiviral state in the CNS

Remarkable early warning system helps the brain prepare for a viral attack

Virus-associated molecules in the foot are enough to trigger the network: Research reveals a remarkable mechanism, in which the brain prepares for a potential viral attack within hours of infection.

News • Fluorescence lifetime imaging microscopy

New technique could aid targeted lung cancer treatment

Detecting genetic mutations associated with lung cancer via laboratory tests can be expensive and time-consuming, and use up valuable tissue from small biopsy samples. A new approach aims to fix this.

Related articles